

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100720-PIP01-22-M02) and to the deferral

MHRA-100720-PIP01-22-M03

Scope of the Application

Active Substance(s)

gepotidacin

Condition(s)

Treatment of uncomplicated urinary tract infections

Pharmaceutical Form(s)

Film-coated tablet Age appropriate oral formulation

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

GlaxoSmithKline UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, GlaxoSmithKline UK Limited submitted to the licensing authority on 31/03/2025 13:09 BST an application for a Modification

The procedure started on 06/05/2025 12:51 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100720-PIP01-22-M03

Of 26/08/2025 17:22 BST

On the adopted decision for gepotidacin (MHRA-100720-PIP01-22-M03) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for gepotidacin, Film-coated tablet Age appropriate oral formulation , ORAL USE .

This decision is addressed to GlaxoSmithKline UK Limited, GSK HQ, 79 New Oxford Street, London, UNITED KINGDOM, WC1A 1DG

ANNEX I

1. Waiver

1.1 Condition:

Treatment of uncomplicated urinary tract infections The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age Pharmaceutical form(s): Film-coated tablet Age appropriate oral formulation Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product is likely to be ineffective

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of uncomplicated urinary tract infections

2.2 Indication(s) targeted by the PIP:

Treatment of uncomplicated urinary tract infections (acute cystitis) in children from 2 years to less than 18 years of age

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet Age appropriate oral formulation

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 (same as Study 1 of MHRA-100714-PIP01-22-M01 and subsequent modifications thereof) Age-appropriate oral dosage form.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	5	Study 2 (209611) (same as Study 2 of MHRA-100714-PIP01-22-M01 and subsequent modifications thereof) Double-blind, randomised, sequential, two-part study to investigate the PK of gepotidacin tablets in healthy adult participants (Part 1) and healthy adolescent participants from 12 to less than 18 years of age (Part 2). Study 3 (204989) Randomised, parallel-group, double blind, double-dummy, active comparator-controlled, non-inferiority study in adolescent female patients from 12 to less than 18 years of age (and adults) with uncomplicated urinary tract infection (acute cystitis), to assess the combined clinical and microbiological efficacy of gepotidacin compared with nitrofurantoin at the test of cure visit. Study 4 (212390) Randomised, parallel-group, double blind, double-dummy, active comparator-

		controlled, non-inferiority study in adolescent female patients from 12 to less than 18 years of age (and adults) with uncomplicated urinary tract infection (acute cystitis), to assess the combined clinical and microbiological efficacy of gepotidacin compared with nitrofurantoin at the test of cure visit. Study 5 (207705) Double blind, randomised, active-controlled comparator study to determine the safety, tolerability and efficacy of repeat oral doses of gepotidacin for 5 days compared with SOC antibacterial treatment. Study 8 (222778) Added during procedure MHRA-100720-PIP01-22-M03 Open-label, add-on, non-comparator study to evaluate the pharmacokinetics and safety of a single dose of oral gepotidacin in addition to antibacterial standard of care in paediatric participants with a suspected or confirmed bacterial infection or receiving prophylaxis with antibiotics.
Extrapolation, Modeling & Simulation Studies	1	Study 6 Population PK analysis (PopPK) to determine a paediatric dose/posology in children from 2 to less than 12 years of age that should achieve the systemic exposures (AUC and Cmax) equivalent to that observed in adults and children from 12 years and older. Study 7 Deleted during procedure MHRA-100720-PIP01-22-M01.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/03/2033
Deferral of one or more studies contained in the paediatric investigation plan:	Yes

